Novartis AG has increased its annual profit forecast for the third consecutive quarter due to strong sales of its leading medications for psoriasis and cancer.
The pharmaceutical company, based in Basel, has stated that its core operating income is expected to rise by a high-teens percentage this year, while sales are projected to grow by low double digits.
These updated targets are positioned at the upper end of Novartis's previous guidance range, highlighting the company's strong performance in the competitive pharmaceutical market.
The positive outlook demonstrates the effectiveness of Novartis's product portfolio in addressing significant health challenges.